Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.91 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.91 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379467 | 1.00 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL682189 | 1.00 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL2105 | 0.98 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Water SCHEMBL10423764 | 0.98 | CYP3A4 (0.94) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL10336934 | 0.97 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL3517972 | 0.95 | SLC6A4 (1.00) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL15065547 | 0.93 | SLC6A3 (0.85) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL4606333 | 0.88 | CYP3A4 (0.76) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL6419503 | 0.86 | CYP3A4 (0.78) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL12235320 | 0.85 | CYP3A4 (0.72) | CYP3A4ALOX15TSHRTP53SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003523410-A | — | — | 2003-08-05 | — | — | JP | claimed |
| US-20030130355-A1 | Therapeutic agents | KNOLL GMBH (DE) | 2003-07-10 | — | — | US | claimed |
| EP-1259292-A2 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001062341-A2 | COMBINATION PRODUCT FOR THE TREATMENT OF OBESITY | KNOLL GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | claimed |
| WO-2025076210-A1 | CHLAMYDIA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-2261203-B1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | BEIJING YINGU CENTURY PHARMACY CO LTD (CN) | 2016-05-25 | — | — | EP | disclosed |
| EP-2261203-B1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | BEIJING YINGU CENTURY PHARMACY CO LTD (CN) | 2016-05-25 | — | — | EP | disclosed |
| US-8877755-B2 | Dopamine-agonist combination therapy for improving sleep quality | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877755-B2 | Dopamine-agonist combination therapy for improving sleep quality | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8673981-B2 | Phenylcyclobutylamide derivatives and their stereoisomers, the preparation processes and uses thereof | YinGu Pharmaceutical Co., Ltd (CN) | 2014-03-18 | — | — | US | disclosed |
| US-8673981-B2 | Phenylcyclobutylamide derivatives and their stereoisomers, the preparation processes and uses thereof | YinGu Pharmaceutical Co., Ltd (CN) | 2014-03-18 | — | — | US | disclosed |
| WO-2001034140-A1 | PHARMACEUTICAL FORMULATION | ABBOTT GMBH & CO. KG (DE) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001000205-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000187-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND A LIPASE INHIBITOR | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-1039900-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-04 | — | — | EP | disclosed |
| US-6127424-A | N-METHYL-1-(1-(4-CHLOROPHENYL)CYCLOBUTYL)-3-METHYLBUTYLAMINE OR A PHARMACEUTICALLY SUITABLE SALT AS AN EXAMPLE; BIOAVAILABILITY; SIDE EFFECT REDUCTION | KNOLL AKTIENGESESLLSCHAFT (DE) | 2000-10-03 | — | — | US | disclosed |
| WO-2000032182-A1 | THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | disclosed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
| WO-1999033450-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130355-A1 | Therapeutic agents | TPH1, SLC6A2, HTR1A | CYP3A4 1923/4885ALOX15 416/4885TSHR 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.